Saturday, October 3, 2026

Coffee Futures Is 15% Up In The Last 10 Sessions

Coffee Futures Is 15% Up In The Last 10 Sessions

(VIANEWS) - Coffee (KC) has been up by 15.47% for the last 10 sessions. At 05:53 EST on Thursday, 30 May, Coffee (KC) is $229.55.

Volume

Today's last reported volume for Coffee is 2624, 87.61% below its average volume of 21188.16.

Volatility

Coffee's last week, last month's, and last quarter's current intraday variation average was 0.14%, 0.23%, and 2.95%, respectively.

Coffee's highest amplitude of average volatility was 2.18% (last week), 1.89% (last month), and 2.95% (last quarter), respectively.

News about

  • Crude oil eases back on Wednesday, WTI falls back below $79 per barrel. According to FXStreet on Wednesday, 29 May, "Broad-market risk appetite is evaporating in the mid-week as investors balk at declining demand for US Treasuries and energy markets grow concerned ahead of US Crude Oil production counts.", "WTI US Crude Oil fell back under $80.00 per barrel on Wednesday, and crossing below the 200-day Exponential Moving Average (EMA) at $79.16. "
  • Crude oil extends gains, WTI breaks $80 as markets look to opec+. According to FXStreet on Tuesday, 28 May, "US Crude Oil is on pace to close in the green for a third straight trading day, and remains down from 2024's peaks near $87.00. ", "OPEC begins an online-only meeting on Sunday, June 2, where the Crude Oil alliance is broadly expected to maintain voluntary production caps of 2.2 million bpd that have been in place since the third quarter of 2023. "

More news about Coffee (KC).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com